Related Experiment Video

Updated: Sep 30, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Regulation of miR-30b in cancer development, apoptosis, and drug resistance

Zhen-Jie Fu1, Yan Chen1, Yu-Qin Xu1

  • 1School of Life Sciences, Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou 310053, China.

Open Life Sciences
|March 16, 2022
PubMed

Insights

MicroRNA-30b (miR-30b) inhibits tumor growth, migration, and invasion by regulating key genes and pathways. This microRNA also shows potential in overcoming cancer drug resistance, suggesting future therapeutic applications.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNA-30b (miR-30b), encoded by a gene on chromosome 8q24.22, is implicated in various disease processes.
  • Dysregulation of microRNAs is a hallmark of many cancers, affecting critical cellular functions.

Purpose of the Study:

  • To elucidate the role of miR-30b in cancer progression and drug resistance.
  • To investigate the molecular mechanisms underlying miR-30b's tumor-suppressive functions.

Main Methods:

  • Analysis of miR-30b expression in tumor samples.
  • In vitro studies assessing the effects of miR-30b on cancer cell proliferation, migration, invasion, and apoptosis.
  • Investigation of miR-30b's impact on the PI3K/AKT signaling pathway and epithelial-mesenchymal transition (EMT).

Main Results:

  • miR-30b significantly inhibits cancer cell proliferation, migration, and invasion across various tumor types.
  • miR-30b suppresses the PI3K/AKT signaling pathway by targeting genes such as EGFR, AKT, Derlin-1, GNA13, and SIX1.
  • miR-30b effectively inhibits tumor cell EMT and promotes apoptosis.
  • miR-30b demonstrates a significant role in overcoming drug resistance in cancer cells.

Conclusions:

  • miR-30b functions as a potent tumor suppressor by inhibiting cancer cell aggressiveness and EMT.
  • miR-30b holds promise for overcoming drug resistance and represents a potential therapeutic target in oncology.
  • Further research is warranted to explore the clinical utility of miR-30b as a diagnostic marker or anticancer agent.
Keywords:
cancer developmentdrug resistancemiR-30bmolecular mechanismsignaling pathways

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.7K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.3K